Vir Biotechnology Files 8-K

TL;DR

Vir Bio filed an 8-K on 5/9/25. Standard reporting.

AI Summary

Vir Biotechnology, Inc. filed an 8-K on May 9, 2025, reporting other events and financial statements. The filing details the company's principal executive offices located at 1800 Owens Street, Suite 900, San Francisco, California, 94158.

Why It Matters

This 8-K filing indicates routine corporate reporting by Vir Biotechnology, Inc., providing updates on company events and financial disclosures.

Risk Assessment

Risk Level: low — This filing is a routine 8-K for Vir Biotechnology, Inc. and does not appear to contain significant new information that would immediately impact the company's risk profile.

Key Numbers

• 415-906-4324 — Phone Number (Registrant's Telephone Number)

Key Players & Entities

• Vir Biotechnology, Inc. (company) — Registrant
• May 9, 2025 (date) — Date of Report
• 1800 Owens Street, Suite 900, San Francisco, California, 94158 (location) — Principal Executive Offices
• 001-39083 (identifier) — Commission File Number
• 81-2730369 (identifier) — IRS Employer Identification No.

FAQ

From the Filing

0001628280-25-024067.txt : 20250509 0001628280-25-024067.hdr.sgml : 20250509 20250509082353 ACCESSION NUMBER: 0001628280-25-024067 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250509 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250509 DATE AS OF CHANGE: 20250509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 25928483 BUSINESS ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 1800 OWENS STREET STREET 2: SUITE 900 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 8-K 1 vir-20250509.htm 8-K vir-20250509 FALSE 0001706431 0001706431 2025-05-09 2025-05-09 0001706431 exch:XNAS 2025-05-09 2025-05-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 ________________________________________ Vir Biotechnology, Inc. (Exact name of Registrant as Specified in Its Charter) ________________________________________ Delaware 001-39083 81-2730369 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 1800 Owens Street , Suite 900 San Francisco , California 94158 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: ( 415 ) 906-4324 (Former Name or Former Address, if Changed Since Last Report) ________________________________________ Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, $0.0001 par value VIR Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company o If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o Item 8.01 Other Events On May 9, 2025, Vir Biotechnology, Inc. (the Company) issued a press release announcing 24-week post-end of treatment data from Part B of its ongoing MARCH Phase 2 clinical study evaluating tobevibart, an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen, and elebsiran, an investigational hepatitis B virus-targeting small interfering ribonucleic acid, with or without pegylated interferon alpha, for the treatment of participants living with chronic hepatitis B. The Company has not secured a development partner for the chronic hepatitis B program to date, and will not allocate additional res